… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… N.V. entered into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected … research collaboration with Galapagos, where the company’s Axiomer ® technology will be applied to certain fibrosis … partnering and other strategic relationships for the Axiomer ® platform in select therapeutic areas Entered into a …
… Scientific Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, … to provide strategic oversight of ProQR’s proprietary Axiomer RNA-editing platform technology. He is the scientific … new strategy, including further building out the Company’s Axiomer RNA-editing technology as a value-generating …
… our earlier-stage pipeline candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” … through intravitreal injections in the eye. About Axiomer and Trident ProQR is pioneering a next-generation RNA … yield a new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides”, or EONs, mediate single …
… EST This presentation will highlight ProQR’s proprietary Axiomer ® platform, a fully owned and in house developed RNA … in the retina with oligonucleotide therapeutics. About Axiomer ® platform technology ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.